Abstract

Parkinson's disease (PD) is second most common neurodegenerative disorder. With the increasing worldwide aging population, prevalence is also expected to increase dramatically. The clinical symptoms of PD can be divided into non-motor and motor symptoms. The non-motor symptoms start earlier in the disease course before the onset of motor symptoms. The treatment of motor symptoms of PD began with the use of anticholinergics many decades ago before the milestone treatment with levodopa was discovered in the 1960s. Several dopaminergic and non-dopaminergic drugs have been developed. Focus has also shifted to the treatment of non-motor symptoms. Besides oral therapy, continuous infusion therapy, ablation therapy, and neuromodulator therapy have also been developed. Now the focus is changing from symptomatic treatments to decreasing the progression or curing the disease.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call